Literature DB >> 16100299

Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients.

Vendel Kemény1, Sándor Molnár, Mónika Andrejkovics, Attila Makai, László Csiba.   

Abstract

A double-blind, prospective, randomized, placebo-controlled clinical trial was carried out to test the acute and long-term hemodynamical and beneficial cognitive effects of the vasoactive agent vinpocetine on patients suffering from multiple cerebral infarcts by means of functional transcranial Doppler examinations and by neuropsychological tests. Twenty-six patients (17 men, 9 women) with multiple cerebral infarctions, aged between 50 and 83 years (mean age+/-SD=63.4+/-9.39 years) were examined, 14 of whom received vinpocetine and 12 placebo. The functional transcranial Doppler included breath-holding tests, finger movement, word fluency, and picture-discrimination tasks. Twenty-five patients were assessed by neuropsychological battery. No serious side effect was found in the vinpocetine group. The flow velocities were significantly lower in the acute phase after breath holding in the vinpocetine group than in the placebo group. Three months later, the vinpocetine patients did not show any significant worsening in digit span backward test, while the placebo group did. No other significant differences in the neuropsychological test could be detected between the treatment and the placebo groups. Longer lasting and higher dosage of vinpocetine therapy is suggested to prove its potential effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100299     DOI: 10.1177/0091270005279363

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

Review 1.  Alternative medicine and Alzheimer disease.

Authors:  Brendan J Kelley; David S Knopman
Journal:  Neurologist       Date:  2008-09       Impact factor: 1.398

Review 2.  Vinpocetine for acute ischaemic stroke.

Authors:  D Bereczki; I Fekete
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 3.  DNA Damage: A Main Determinant of Vascular Aging.

Authors:  Paula K Bautista-Niño; Eliana Portilla-Fernandez; Douglas E Vaughan; A H Jan Danser; Anton J M Roks
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

4.  Influence of angiotensin-converting enzyme inhibition on reversibility of alterations in arterial wall and cognitive performance associated with early hypertension: A follow-up study.

Authors:  Enikő Csikai; Mónika Andrejkovics; Bernadett Balajthy-Hidegh; Gergely Hofgárt; László Kardos; Ágnes Diószegi; Róbert Rostás; Katalin Réka Czuriga-Kovács; Éva Csongrádi; László Csiba
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders.

Authors:  Thomas E Krahe; Weili Wang; Alexandre E Medina
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

6.  Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.

Authors:  Jianhui Zhuang; Wenhui Peng; Hailing Li; Yuyan Lu; Ke Wang; Fan Fan; Shuang Li; Yawei Xu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.